Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 176373, 8 pages
http://dx.doi.org/10.1155/2015/176373
Research Article

The Significance of Metastasectomy in Patients with Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy

1Department of Urology, Peking University First Hospital, Institute of Urology, National Urological Cancer Center, Peking University, Beijing 100034, China
2Department of Orthopedics, Peking University First Hospital, Beijing 100034, China
3Department of Thoracic Surgery, Peking University First Hospital, Beijing 100034, China

Received 14 June 2015; Revised 5 August 2015; Accepted 13 August 2015

Academic Editor: Andrea Minervini

Copyright © 2015 Xiaoteng Yu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2013,” CA Cancer Journal for Clinicians, vol. 63, no. 1, pp. 11–30, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Staehler, N. Haseke, G. Schoeppler, T. Stadler, C. Gratzke, and C. G. Stief, “Modern therapeutic approaches in metastatic renal cell carcinoma,” EAU-EBU Update Series, vol. 5, no. 1, pp. 26–37, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. H. T. Cohen and F. J. McGovern, “Renal-cell carcinoma,” The New England Journal of Medicine, vol. 353, no. 23, pp. 2477–2490, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. G. H. J. Mickisch, A. Garin, H. van Poppel, L. de Prijck, and R. Sylvester, “Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial,” The Lancet, vol. 358, no. 9286, pp. 966–970, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. B. I. Rini, S. C. Campbell, and B. Escudier, “Renal cell carcinoma,” The Lancet, vol. 373, no. 9669, pp. 1119–1132, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Coppin, F. Porzsolt, A. Awa, J. Kumpf, A. Coldman, and T. Wilt, “Immunotherapy for advanced renal cell cancer,” The Cochrane Database of Systematic Reviews, no. 1, Article ID CD001425, 2005. View at Google Scholar · View at Scopus
  7. R. M. Bukowshi, “Cytokine therapy for metastatic renal cell carcinoma,” Seminars in Urologic Oncology, vol. 19, no. 2, pp. 148–154, 2001. View at Google Scholar · View at Scopus
  8. R. J. Motzer, B. I. Rini, R. M. Bukowski et al., “Sunitinib in patients with metastatic renal cell carcinoma,” The Journal of the American Medical Association, vol. 295, no. 21, pp. 2516–2524, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. B. Escudier, T. Eisen, W. M. Stadler et al., “Sorafenib in advanced clear-cell renal-cell carcinoma,” The New England Journal of Medicine, vol. 356, no. 2, pp. 125–134, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Escudier, A. Pluzanska, P. Koralewski et al., “Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial,” The Lancet, vol. 370, no. 9605, pp. 2103–2111, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. B. I. Rini, “Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions,” Clinical Cancer Research, vol. 13, no. 4, pp. 1098–1106, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. B. I. Rini, “Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma,” Cancer, vol. 115, no. 10, supplement, pp. 2306–2312, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Lopez-Beltran, M. Scarpelli, R. Montironi, and Z. Kirkali, “2004 WHO classification of the renal tumors of the adults,” European Urology, vol. 49, no. 5, pp. 798–805, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. F. Duffaud and P. Therasse, “New guidelines to evaluate the response to treatment in solid tumors,” Bulletin du Cancer, vol. 87, no. 12, pp. 881–886, 2000. View at Google Scholar · View at Scopus
  15. R. C. Flanigan, G. Mickisch, R. Sylvester, C. Tangen, H. Van Poppel, and E. D. Crawford, “Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis,” The Journal of Urology, vol. 171, no. 3, pp. 1071–1076, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Zini, U. Capitanio, P. Perrotte et al., “Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma,” Urology, vol. 73, no. 2, pp. 342–346, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. M. R. Abern, E. Scosyrev, M. Tsivian, E. M. Messing, T. J. Polascik, and A. Z. Dudek, “Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era,” Anticancer Research, vol. 34, no. 5, pp. 2405–2412, 2014. View at Google Scholar · View at Scopus
  18. A. L. Alt, S. A. Boorjian, C. M. Lohse, B. A. Costello, B. C. Leibovich, and M. L. Blute, “Survival after complete surgical resection of multiple metastases from renal cell carcinoma,” Cancer, vol. 117, no. 13, pp. 2873–2882, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Naito, H. Kinoshita, T. Kondo et al., “Prognostic factors of patients with metastatic renal cell carcinoma with removed metastases: a multicenter study of 556 patients,” Urology, vol. 82, no. 4, pp. 846–851, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Ruutu, P. Bono, and K. Taari, “Resection of renal cell cancer metastases: where do we stand in 2008?” European Urology Supplements, vol. 7, no. 5, pp. 436–442, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. H.-S. Hofmann, H. Neef, K. Krohe, P. Andreev, and R.-E. Silber, “Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma,” European Urology, vol. 48, no. 1, pp. 77–81, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. L. Tosco, H. Van Poppel, B. Frea, G. Gregoraci, and S. Joniau, “Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma,” European Urology, vol. 63, no. 4, pp. 646–652, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. R. J. Motzer, J. Bacik, L. H. Schwartz et al., “Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma,” Journal of Clinical Oncology, vol. 22, no. 3, pp. 454–463, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. J. J. Ko, W. Xie, N. Kroeger et al., “The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study,” The Lancet Oncology, vol. 16, no. 3, pp. 293–300, 2015. View at Publisher · View at Google Scholar · View at Scopus